Synthetic Approaches to New Drugs Approved During 2016 - Journal


2 days ago - This annual review describes the most likely process-scale synthetic approaches to nineteen new chemical entities (NCEs) that were approv...
162 downloads 13 Views 1MB Size

Recommend Documents


Apr 5, 2018 - Prior to joining Pfizer, she was a postdoctoral fellow working with Professor Daniel Romo at Texas A&M University exploring new applications of nucleophile-catalyzed aldol lactonization reactions. Biography. Sarah Fink is a Senior Manag

Andrew C. Flick earned a B.A. in Chemistry from Lake Forest College and then joined Abbott Laboratories' Diagnostics Group in Abbott Park, Illinois. ... In 2003, he joined Professor Albert Padwa's laboratory at Emory University where he ...

Apr 5, 2018 - Hongxia is the cofounder and Chief Executive Officer of PHARMACODIA, a company founded in 2013, which is an online platform (http://www.pharmacodia.com) providing big data and information service in the pharmaceutical R&D field. In 2010

4 days ago - Abstract: New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical ...

Andrew C. Flick,1 Carolyn A. Leverett,2 Hong X. Ding,3 Emma McInturff,4 Sarah ..... antiviral agent approved for the first time in Japan in 2017 for the treatment of ...

Apr 19, 2017 - The most likely process-scale synthetic approach to brexpiprazole follows a 2013 Otsuka patent which describes the kilogram scale of the final API and a key ...... U.S. Food and Drug Administratio: Silver Spring, MD, 2016; http://www.a

Publication Date (Web): April 19, 2017 ... the cofounder and Chief Executive Officer of PHARMACODIA, a company founded in 2013, which is an online platform (http://www.pharmacodia.com) providing big data and information service in ... Citation data i

Apr 19, 2017 - Hongxia is the cofounder and Chief Executive Officer of PHARMACODIA, a company founded in 2013, which is an online platform (http://www.pharmacodia.com) providing big data and information service in the pharmaceutical R&D field. In 201

Apr 19, 2017 - Kevin K.-C. Liu is currently a Director at the Global Discovery Chemistry of Novartis Institute of BioMedical Research and he is located in Shanghai, China, since 2015. He received his B.S. in Chemistry from National Taiwan University,

1 day ago - Abstract: New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical ...